The Supreme Court moved Monday to block an appeals court decision that threatened to severely curtail access to mifepristone, the medication used in roughly half of all U.S. abortions. Justice Samuel Alito issued two brief orders preserving the drug's current nationwide availability while the full court considers emergency filings from its manufacturers.
The freeze lasts until at least May 11, giving the justices a runway to decide whether to take the case or let lower court proceedings continue. Louisiana must respond to the manufacturers' requests by end of business Thursday.
The pressure had intensified Friday when the 5th U.S. Circuit Court of Appeals sided with Louisiana, voting to void Biden administration rules that eliminated the requirement for patients to pick up mifepristone in person. Those rules, originally introduced during the pandemic, effectively allow the drug to be distributed by mail nationwide, reaching patients even in states with near-total abortion bans.
Danco Laboratories manufactures Mifeprex, the brand-name version. GenBioPro produces a generic alternative. Both companies challenged Louisiana's effort to restore stricter distribution limits, arguing the state lacks legal standing to sue over federal drug policy.
The case carries outsized stakes in the post-Dobbs era. When the Supreme Court eliminated the constitutional right to abortion in 2022, it handed conservative states authority over surgical procedures, yet medication abortion presents a harder regulatory target. Pills dispensed through mail systems operate largely beyond state control, potentially reaching patients across state lines regardless of local prohibitions.
This is not the court's first brush with mifepristone battles. In 2024, the justices rejected an earlier bid to overturn the FDA's original approval of the drug, ruling that challengers lacked legal standing. The current dispute narrows its focus to the 2023 administrative decision making pandemic-era flexibilities permanent.
Alito's intervention, while procedurally limited, suggests the court will engage substantively with the underlying questions. The conservative justice's involvement in granting the stay does not necessarily forecast how the full bench will ultimately rule, but it signals the case will receive full court attention rather than swift dismissal.
Author Sarah Mitchell: "The court's move buys breathing room for manufacturers but leaves the biggest question hanging: whether states can reshape federal drug policy through the back door of litigation."
Comments